| Thiadiazole—A promising structure in medicinal chemistry Y Li, J Geng, Y Liu, S Yu, G Zhao ChemMedChem 8 (1), 27-41, 2013 | 291 | 2013 |
| Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma L Zhang, Y Yao, S Zhang, Y Liu, H Guo, M Ahmed, T Bell, H Zhang, G Han, ... Science translational medicine 11 (491), eaau1167, 2019 | 202 | 2019 |
| Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry WH Guo, X Qi, X Yu, Y Liu, CI Chung, F Bai, X Lin, D Lu, L Wang, J Chen, ... Nature communications 11 (1), 4268, 2020 | 133 | 2020 |
| Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents Y Liu, Y Li, S Yu, G Zhao Current drug targets 13 (11), 1432-1444, 2012 | 81 | 2012 |
| B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy L Zhang, K Nomie, H Zhang, T Bell, L Pham, S Kadri, J Segal, S Li, ... Clinical Cancer Research 23 (15), 4212-4223, 2017 | 55 | 2017 |
| Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma P Jain, S Zhao, HJ Lee, HA Hill, CY Ok, R Kanagal-Shamanna, ... Journal of Clinical Oncology 40 (2), 202-212, 2022 | 52 | 2022 |
| Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma S Zhang, VC Jiang, G Han, D Hao, J Lian, Y Liu, R Zhang, J McIntosh, ... Nature communications 12 (1), 2877, 2021 | 44 | 2021 |
| Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib F Ran, Y Liu, C Wang, Z Xu, Y Zhang, Y Liu, G Zhao, Y Ling European Journal of Medicinal Chemistry 229, 114009, 2022 | 37 | 2022 |
| Discovery of novel pyrazole derivatives as potential anticancer agents in MCL F Ran, Y Liu, D Zhang, M Liu, G Zhao Bioorganic & medicinal chemistry letters 29 (9), 1060-1064, 2019 | 32 | 2019 |
| TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma VC Jiang, D Hao, P Jain, Y Li, Q Cai, Y Yao, L Nie, Y Liu, J Jin, W Wang, ... Molecular cancer 21 (1), 185, 2022 | 29 | 2022 |
| Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma CJ Li, C Jiang, Y Liu, T Bell, W Ma, Y Ye, S Huang, H Guo, H Zhang, ... Molecular cancer therapeutics 18 (2), 267-277, 2019 | 28 | 2019 |
| Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors Z Zhang, D Zhang, Y Liu, D Yang, F Ran, ML Wang, G Zhao Archiv der Pharmazie 351 (7), 1700369, 2018 | 28 | 2018 |
| Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo [3, 4-d] pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle … F Ran, Y Liu, S Yu, K Guo, W Tang, X Chen, G Zhao Bioorganic Chemistry 94, 103367, 2020 | 25 | 2020 |
| The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma S Huang, C Jiang, H Zhang, T Bell, H Guo, Y Liu, Y Yao, D Zeng, ... Blood cancer journal 8 (3), 33, 2018 | 22 | 2018 |
| The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma VC Jiang, Y Liu, A Jordan, J McIntosh, Y Li, Y Che, KA Jessen, ... Journal of Hematology & Oncology 14 (1), 132, 2021 | 21 | 2021 |
| Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL F Ran, Y Liu, M Liu, D Zhang, P Wang, J Dong, W Tang, G Zhao Bioorganic Chemistry 89, 102943, 2019 | 21 | 2019 |
| Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma H Guo, D Zeng, H Zhang, T Bell, J Yao, Y Liu, S Huang, CJ Li, E Lorence, ... Oncogene 38 (11), 1802-1814, 2019 | 21 | 2019 |
| Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity Y Liu, Y Yin, Z Zhang, CJ Li, H Zhang, D Zhang, C Jiang, K Nomie, ... European journal of medicinal chemistry 138, 543-551, 2017 | 19 | 2017 |
| Design, synthesis and evaluation of novel indole derivatives as AKT inhibitors D Yang, P Wang, J Liu, H Xing, Y Liu, W Xie, G Zhao Bioorganic & medicinal chemistry 22 (1), 366-373, 2014 | 18 | 2014 |
| Design and discovery of 5-hydroxy-6-oxo-1, 6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase D Zhang, B Debnath, S Yu, TW Sanchez, F Christ, Y Liu, Z Debyser, ... Bioorganic & medicinal chemistry 22 (19), 5446-5453, 2014 | 17 | 2014 |
